Universal Health Services stock price target maintained at $226 by TD Cowen

Published 29/07/2025, 17:08
Universal Health Services stock price target maintained at $226 by TD Cowen

Investing.com - TD Cowen has reiterated its Buy rating on Universal Health Services (NYSE:UHS) with a price target of $226.00, according to a research note issued by the firm. Currently trading at $160.39, the stock appears undervalued according to InvestingPro’s Fair Value model, with a P/E ratio of just 8.9x.

The healthcare services provider posted adjusted EBITDA that exceeded consensus estimates by 5%, despite facing a $25 million drag from its DC hospital operations during the quarter.

The company benefited from a $101 million net Directed Payment Program (DPP) contribution, including payments from Tennessee, which analysts may not have fully incorporated into their second-quarter 2025 estimates.

Universal Health Services has raised its fiscal year 2025 EBITDA midpoint guidance by 3.3%, accounting for anticipated DPP payments from Tennessee and other sources, while also factoring in new DC hospital operational challenges and lower behavioral volumes.

The net effect of these adjustments resulted in an $80 million increase to the company’s EBITDA guidance for the full year.

In other recent news, Universal Health Services reported its second-quarter 2025 earnings, exceeding analyst expectations. The company achieved an adjusted earnings per share (EPS) of $5.35, surpassing the projected $4.93, marking an 8.52% surprise. Revenue also outperformed forecasts, reaching $4.28 billion compared to the anticipated $4.24 billion. These results highlight the company’s strong performance in the quarter. Additionally, various analyst firms have taken note of these developments, with some adjusting their ratings on the stock. While specific upgrades or downgrades were not detailed in the reports, the earnings beat has certainly drawn attention from the analyst community. Investors are likely to keep a close watch on Universal Health Services as these financial results reflect robust business operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.